SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : momo-T/FIF
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Miljenko Zuanic11/5/2018 2:01:06 PM
  Read Replies (2) of 12215
 
RE: Topic NASH, Subtopic GLMD 3Q cc

After Arrest study, they plan for FDA P3 protocol meting by year-end (or end-of-P2b). IF they plan only single P3, should that incorporate SPA? And more "deep" FDA interaction? IF they are still trying to increase Aramchol drug exposure (by new formulation without dose increase, I guess),...should that be also part of FDA discussion? I am afraid that they will need first another P2 (dose-exposure relation), and than P3. Can this be reason for "NO-partner" so far?

Disclosure, after recent decline in SP, I re-enter position on GLMD, mostly as trade opportunity.

PS: Plan for 600 Kg API quantity is nice to hear.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News